Sanofi's dual-action biotech asthma drug performs well in test
November 11, 2014 at 03:39 AM EST
Nov 11 (Reuters) - An experimental biotech drug for severe asthma from France's Sanofi and its U.S. partner Regeneron has produced good results in clinical tests, suggesting its dual-action mechanism may be highly effective.